Recent Finacing
Recent Raise
NewAmsterdam Pharma is a clinical-stage company developing obicetrapib, a CETP inhibitor that reduces ApoB and LDL‑c for cardiometabolic risk, advancing from Phase 2 to Phase 3, based in Naarden, Netherlands.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
